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INTRODUCTION
Moraxella (Branhamella) catarrhalis, formerly called Neisse-
ria catarrhalis or Micrococcus catarrhalis, is a gram-negative,
aerobic diplococcus frequently found as a commensal of the
upper respiratory tract (124, 126; G. Ninane, J. Joly, P. Piot,
and M. Kraytman, Letter, Lancet ii:149, 1997). Over the last 20
to 30 years, the bacterium has emerged as a genuine pathogen
and is now considered an important cause of upper respiratory
tract infections in otherwise healthy children and elderly peo-
ple (48, 108, 132, 168). Moreover, M. catarrhalis is an impor-
tant cause of lower respiratory tract infections, particularly in
adults with chronic obstructive pulmonary disease (COPD)
(48, 108, 168). In immunocompromized hosts, the bacterium
can cause a variety of severe infections including pneumonia,
endocarditis, septicemia, and meningitis (48, 63, 72). In addi-
tion, hospital outbreaks of respiratory disease due to M. ca-
tarrhalis have been described (188, 200), now establishing the
bacterium as a nosocomial pathogen. Because M. catarrhalis
has long been considered a harmless commensal (48, 124, 126),
relatively little is known about its pathogenic characteristics
and virulence factors, although developments in this field of
research have accelerated over the past 5 years.
The emergence of M. catarrhalis as a pathogen in the last
decade, together with the increasing prevalence of -lacta-
* Corresponding author. Mailing address: Department of Medical
Microbiology & Infectious Diseases, Erasmus University Medical Cen-
ter Rotterdam EMCR, Dr. Molewaterplein 40, 3015 GD Rotterdam,
The Netherlands. Phone: 31-10-4633510. Fax: 31-10-4633875. E-mail:
verduin@bacl.azr.nl.
125
mase-producing strains, has renewed interest in this bacterial
species. In this review, we will summarize important features of
this organism, focusing on microbial epidemiology, virulence,
immunity, and clinical and molecular-pathogenic aspects of
infections caused by this organism.
TAXONOMY
In the past, M. catarrhalis was considered a nonpathogenic
member of the resident flora of the nasopharynx. It was one of
the species belonging to the so-called nongonococcal, nonme-
ningococcal neisseriae, considered to be members of the nor-
mal flora. The name of the species has caused considerable
confusion. The bacterium was first described in 1896 (98) and
was called Micrococcus catarrhalis. Later it was renamed Neis-
seria catarrhalis. In 1963, Berger showed that the original genus
Micrococcus catarrhalis actually contained two distinct species,
Neisseria cinerea and N. catarrhalis (16). These species could be
separated based on the results of nitrate and nitrite reduction
and tributyrin conversion testing. Because of the wide phylo-
genetic separation between N. catarrhalis and the so-called
“true” Neisseria species, observed by a variety of a methods, the
bacterium was moved to the new genus Branhamella in honour
of Sara E. Branham (49). In 1984, B. catarrhalis was reassigned
to the genus Moraxella as Moraxella (Branhamella) catarrhalis
(34). This genus now contains both coccoid and rod-shaped
bacteria, which are genetically related. The position of M.
catarrhalis in the prokaryotic kingdom is shown in Fig. 1. DNA
sequencing has substantiated the validity of the current taxo-
nomic classification (84, 191). Many scientists preferred the
name Branhamella catarrhalis, and in several recent publica-
FIG. 1. The bacterial species M. catarrhalis and its close relatives. (A) Position of the  proteobacteria in the prokaryotic kingdom. M. catarrhalis
is within this class of organisms. (B) More detailed positioning of M. catarrhalis in the order Pseudomonales. Panel A reprinted from reference 106
with permission of the publisher; the data in panel B are derived from Bergey’s Manual of Determinative Bacteriology, 8th ed. (R. E. Buchanan and
N. E. Gibbons, ed.), The Williams & Wilkins Co. Baltimore, Md. (web-accessible version).
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tions this name is primarily used. As a means of resolving this
semantic problem, Catlin (47) has proposed the formation of a
new family, Branhamaceae, to accommodate the genera
Moraxella and Branhamella. However, comparison of 16S
rDNA sequences of Moraxella spp. and these from bacterial
species in related genera has demonstrated the close relation
of M. catarrhalis to M. lacunata subsp. lacunata and to a “false”
Neisseria species, N. ovis. In addition, M. catarrhalis appears to
be more closely related to Acinetobacter spp. than to Neisseria
spp. (84). On the basis of these results, the latter authors
conclude that there is no rationale for a separate Branhamella
genus. Consequently, M. catarrhalis is the currently preferred
name for this bacterial species.
ISOLATION AND IDENTIFICATION
Isolation of M. catarrhalis from clinical specimes, e.g., spu-
tum, can be complicated by the presence of nonpathogenic
neisseriae. Selective agar media have been used to isolate M.
catarrhalis with some success. For example, acetazolamide,
which reduces the growth of Neisseria species when used under
aerobic conditions, and the antimicrobial components vanco-
FIG. 1—Continued.
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mycin, trimethoprim, and amphotericin B may be included in
an agar medium to inhibit the growth of the normal flora (71,
227).
Over the years, the following criteria have been used to
unambiguously distinguish M. catarrhalis from other bacterial
species: Gram stain; colony morphology; lack of pigmentation
of the colony on blood agar; oxidase production; DNase pro-
duction; failure to produce acid from glucose, maltose, su-
crose, lactose, and fructose; growth at 22°C on nutrient agar;
failure to grow on modified Thayer-Martin medium; and, fi-
nally, reduction of nitrate and nitrite (76, 214). However, it has
been shown that growth at 22°C and failure to grow on mod-
ified Thayer-Martin medium are not reliable parameters for
the correct identification of M. catarrhalis (76). Also, Jo¨nsson
et al. (128) showed that colony morphology, Gram stain, and
oxidase production were an insufficient group of characteristics
to permit correct and final identification of M. catarrhalis in
cultures derived from sputum samples. It should be noted,
however, that the Gram stain still plays a crucial role both in
the isolation of the bacterium from clinical material (e.g., spu-
tum) and in its subsequent identification. In typical Gram
stains, M. catarrhalis presents itself as a gram-negative diplo-
coccus with flattened abutting sides. The bacterium has a ten-
dency to resist destaining. Colonies on blood agar are nonhe-
molytic, round, opaque, convex, and greyish white. The colony
remains intact when pushed across the surface of the agar. The
bacteria are oxidase positive, but additional tests are needed
for routine identification. Positive reactions for DNase produc-
tion, reduction of nitrate and nitrite, and tributyrin hydrolysis
are valuable differentiating characteristics (48, 214, 217). Ac-
cording to Catlin (48), the identity of M. catarrhalis is best
confirmed by positive reactions in at least three of these dif-
ferentiating tests, since none of them is 100% sensitive or
specific by itself.
Modern DNA technology has opened new avenues for the
detection of M. catarrhalis in clinical materials (e.g., middle ear
effusion) without the need for bacterial culture. In particular,
PCR tests for M. catarrhalis have been both designed and used
for clinical purposes, with direct detection of M. catarrhalis
DNA by PCR being concordant with culture and endotoxin
detection. However, DNA assays yield significantly more pos-
itive results than does culture when, for instance, middle ear
effusions are analyzed, which suggests superior sensitivity of
the DNA amplification assays (70). The clinical relevance of
PCR has been validated extensively in the chinchilla model for
otitis media. This animal model was instrumental in demon-
strating the quick and effective effusion-mediated clearance of
DNA and dead M. catarrhalis bacteria from the middle ear
cleft, implying that in this case a positive PCR result was
indicative of the presence of viable bacteria (193). Moreover,
PCR has also been reliably used for the detection of mixed
infections in the same experimental-infection model (11),
thereby substantiating the applicability of multiplex PCR ap-
proaches for the detection of mixed bacterial infections, e.g.,
with M. catarrhalis, Haemophilus influenzae, and Streptococcus
pneumoniae in a single amplification assay. This approach has
even been successful for culture-negative effusion (194). Re-
cently, clinical evaluation of a multiplex PCR specific for the
above three pathogens plus Alloiococcus otitidis demonstrated
that reliable DNA amplification-based diagnostics of middle
ear effusions can be performed in a single working day (113).
Furthermore, the sensitivity of the PCR tests corresponds to
six or seven genome equivalents, making PCR an unrivaled
diagnostic assay (195). However, it has to be emphasized that
the technical demands of PCR are still beyond the capacities of
many routine microbiology laboratories, although improve-
ments in robotics and other forms of laboratory automation
are fast bridging the current gap between theory and practice.
EPIDEMIOLOGY
For several reasons, epidemiological studies of M. catarrhalis
are difficult. Practical typing systems have become available
only recently, and the lack of reliable serological tests is at least
partly to blame for this problem. Moreover, the clinical interest
in M. catarrhalis is only relatively recent, and many laboratories
did not report M. catarrhalis as a pathogen, especially when a
well-recognized pathogen (e.g., S. pneumoniae or H. influen-
zae) was present as well. In addition, as mentioned above, the
isolation of M. catarrhalis from sputa is complicated by the
presence of nonpathogenic neisseriae. Thus, the use of selec-
tive agar media could be advantageous (71, 227).
Conventional and Molecular Typing Systems
Several phenotyping strategies have been described for ep-
idemiological typing of M. catarrhalis, although none of these
has been accepted internationally. Serological typing of lipo-
polysaccharide (LPS) (230), isoelectric focusing of -lactamase
proteins (179), and electrophoretic profiling of outer mem-
brane proteins (13) have been described but have never been
used in large-scale studies. Besides these and some other
regularly employed phenotyping procedures (66, 190), other
methods based on nucleic acid polymorphism have become
available more recently. Comparison of restriction endonu-
clease analysis with phenotyping (57) has indicated that
restriction endonuclease analysis of genomic DNA can be used
successfully for delineation of disease outbreaks (134, 188).
Also, macrorestriction enzymes and pulsed-field gel electro-
phoresis have been used to shed light on matters of epidemi-
ological concern (237, 254). An example of the use of PFGE to
document patient-to-patient transmission is shown in Fig. 2.
The use of strain-specific DNA probes has also been docu-
mented (14, 243). Recent studies identified amplified fragment
length polymorphism analysis and automated ribotyping as
useful typing procedures (32, 235). Moreover, when these two
strategies were used, complement-resistant strains of M. ca-
tarrhalis were found to form a distinct clonal lineage within the
species (Fig. 3) (32, 235). These observations are in agreement
with earlier studies identifying M. catarrhalis as a genetically
heterogeneous species from which successful clones occasion-
ally proliferate (85). Expansion of such competitive types has
also been documented during distinct periods and in particular
geographic regions (157). Frequent horizontal gene transfer
seems possible (31, 150), and in relation to the observations
made for complement resistance, it may be postulated that
other phenotypic traits could be acquired through cross-spe-
cies gene acquisition. For instance, Bootsma et al. (31)
demonstrated that the barrier between M. catarrhalis and
gram-positive microorganisms may be occasionally crossed by
antimicrobial resistance genes.
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Carriage
The M. catarrhalis carriage rate in children is high (up to
75%) (89, 230, 231). In contrast, the carriage rate of M. ca-
tarrhalis in healthy adults is very low (about 1 to 3%) (69; T.
Ejlartsen, Letter, Eur. J. Clin. Microbiol. Infect. Dis., 10:89,
1991). This inverse relationship between age and colonization
has been known since 1907 (9) and is still present today (81; C.
Hol, C. M. Verduin, E. van Dijke, J. Verhoef, and H. van Dijk,
Letter, Lancet 341:1281, 1993). At present, there is no good
explanation for the difference in rates of colonization between
children and adults; one explanation may be the age-depen-
dent development of secretory immunoglobulin A (IgA). Re-
markably, IgG antibody levels do not correlate with the state of
colonization or with lower respiratory tract infection with M.
catarrhalis in children (82). Interestingly, nasopharyngeal car-
riage rates are significantly higher in winter and autumn than
in spring and summer (230).
Monthly or bimonthly sampling of the nasopharynges of
children (n  120) by Faden et al. (89) revealed the presence
of M. catarrhalis in 77.5% of subjects at least once during the
first 2 years of life. Furthermore, these authors showed a clear
relationship between the frequency of colonization and the
development of otitis media. A small Japanese study revealed
that colonization in children attending a day care center is
highly dynamic (254). Although clusters of genotypes could be
discerned and seemed to persist for periods of 2 to 6 weeks,
frequent changes in the nature of individual colonizing strains
of M. catarrhalis were observed. Of note, rates of isolation of
M. catarrhalis are much higher in fall and winter than in spring
and summer. This seasonal difference in isolation is less pro-
nounced with S. pneumoniae or H. influenzae (230) but is quite
common in viral infections.
Other authors have described a relationship between the
frequency of colonization and the occurrence of upper respi-
ratory infection (40, 196, 230, 231). Klingman et al. (139)
investigated the colonization of the respiratory tract of patients
with bronchiectasis. A subset of these patients was repeatedly
colonized with different M. catarrhalis strains. The patients
were colonized with the same strain for an average of 2.3
months as determined by restriction fragment length polymor-
phism patterns, and colonization with a new strain did not
correlate with changes in clinical status. Although not studied
in detail, there are indications that adults with chronic lung
disease are colonized at a higher rate than are healthy adults
(169).
DISEASES IN CHILDHOOD
M. catarrhalis is now considered an important pathogen in
respiratory tract infections, both in children and in adults with
underlying COPD. Occasionally, the bacterium causes sys-
temic disease, e.g., meningitis and sepsis (2, 48, 59, 75). Bac-
teremia due to M. catarrhalis should be considered especially in
febrile children with an underlying immune dysfunction and an
upper respiratory tract infection (2). In addition, M. catarrhalis
may be the single cause of sinusitis, otitis media, tracheitis,
bronchitis, pneumonia, and, less commonly, ocular infections
in children. In children, nasopharyngeal colonization often
precedes the development of M. catarrhalis-mediated disease
(89). Below we summarize the clinical features of childhood
disease.
Sinusitis
Sinus development is a process that may take up to 20 years,
although the ethmoid and maxillary sinuses are already present
at birth; the development of sphenoid and frontal sinuses starts
in the first few years of life (55). Sinusitis is a very common
infection in early childhood, accounting for about 5 to 10% of
upper respiratory tract infections (239, 240; E. R. Wald, Edi-
torial, Pediatr. Ann. 27:787–788, 1998). It is often underdiag-
nosed in children because the symptoms are nonspecific. In
addition, physical examination and radiology are of little value
in young children, and an etiologic diagnosis requires culturing
an aspirate of sinus secretions (28). In acute sinusitis (where
symptoms are present for 10 to 30 days) and subacute disease
(30 to 120 days), S. pneumoniae, H. influenzae, and M. catarrha-
lis are the most frequently isolated bacterial pathogens (27, 28,
46, 239, 240; Wald, Editorial). S. pneumoniae is found in 30 to
40% of patients, while H. influenzae and M. catarrhalis each
account for approximately 20% of cases. Interestingly, in chil-
dren with asthma, the same distribution of bacterial pathogens
is found (238), although Goldenhersch et al. (103) isolated M.
catarrhalis as the predominant pathogen in subacute or chronic
sinusitis (symptoms present for more than 30 days) in children
with respiratory allergy. It has been suggested that there is a
possible underestimation of isolation rates for M. catarrhalis,
since the bacterium stops growing in environments with re-
duced oxygen concentrations, a condition frequently present
during sinusitis and otitis media (39, 204). This would indicate
an even greater role for M. catarrhalis in the etiology of these
infectious diseases.
FIG. 2. Pulsed-field gel electrophoresis of SpeI-digested M. ca-
tarrhalis DNA. Twenty nosocomial isolates were analyzed, which re-
sulted in the identification of several clusters of indiscriminate strains.
As indicated at the top, isolates 1 and 2 and isolates 17 and 18 are
identical, which fits well with the fact that the strains were isolated
from the same patients on separate occasions. Strains 5, 10, 11, and 13
were isolated from different patients hospitalized during overlapping
time intervals in the same pediatric department. It was concluded that
patient-to-patient transmission occurred in this setting.
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Otitis Media
Acute otitis media (AOM) is a very frequent infection in
children: before the age of 1 year, around 50% of children have
experienced at least one period of AOM. This proportion rises
to 70% at the age of 3 years (136, 222; M. L. Kabongo, Letter,
Am. Fam. Physician 40:34, 39, 1989). Undoubtedly, it is the
most serious and frequent infection caused by M. catarrhalis in
children, and as such M. catarrhalis causes tremendous mor-
bidity and requires the widespread use of antibiotics (20, 58,
88, 89, 97, 136, 137, 230). While not frequently encountered as
a pathogen, M. catarrhalis has been recognized as a specific
pathogen in AOM for nearly 70 years (109). Since 1980, a
marked increase has been reported in the isolation of M. ca-
tarrhalis from middle-ear exudates (26, 141, 155, 213). This
increase in M. catarrhalis isolation to approximately 15 to 20%
(187) has been accompanied by the appearance of -lacta-
mase-producing strains, which now account for approximately
90 to 95% of isolates. However, the exact magnitude of this
apparent increase in isolation rates may not have been ade-
quately measured yet (155), since tympanocentesis and culture
of middle ear fluid are not performed routinely. Patel et al.
(187) cultured the middle ear fluids of 99 children with AOM
and isolated S. pneumoniae, nontypeable H. influenzae, and M.
catarrhalis from 39, 30, and 25% of subjects, respectively.
Again, the isolation rates for M. catarrhalis might be an under-
estimation, given the relatively anaerobic environment of the
middle ear during infection (8). In a study using PCR, M.
catarrhalis DNA was detected in 46.4% of pediatric chronic
middle ear effusion specimens (n  97), compared to 54.6%
for H. influenzae DNA and 29.9% for S. pneumoniae DNA
(194). A large percentage (48%) of specimens was PCR posi-
tive and culture negative, whereas all culture-positive speci-
mens were also PCR positive. It is very unlikely that the PCR-
positive yet culture-negative specimens reflect the persistence
of DNA from old infections (10, 193, 194). The severity of
symptoms and numbers of bacteria in middle ear fluid appear
to be lower for M. catarrhalis than for S. pneumoniae or H.
influenzae (87).
Lower Respiratory Tract Infections
Although lower respiratory tract infections in children are a
common cause of morbidity and even mortality among chil-
dren worldwide, obtaining a microbiological diagnosis is noto-
riously difficult. Most studies use combinations of serological
and conventional microbiological (e.g., culture- or PCR-based)
methods. Many of these methods have only been used within a
research setting and are not always reliable or readily available
to clinicians. As a consequence, data concerning the role of M.
catarrhalis in lower respiratory tract infections are not conclu-
sive. Lower respiratory tract infections due to M. catarrhalis
appear to be relatively rare during childhood, with most infec-
tions occurring in children below the age of 1 year (35). Korppi
FIG. 3. Dendrogram constructed on the basis of RiboPrint pattern types obtained for 13 complement-sensitive and 2 complement-resistant
strains of M. catarrhalis (235). Selected were those RiboPrint patterns that are representative of the diverse genogroups that could be identified.
The resistant strains appear to be a more homogeneous group (only 2 closely related types encountered among 47 strains) than are the
complement-sensitive strains. The tree was constructed in the BioNumerics program developed by Applied Maths (Kortrijk, Belgium). On the basis
of Pearson coefficients and unweighted pair group method using arithmetic averages (UPGMA), patterns were normalized using molecular size
markers coanalyzed during pattern creation. The 40 to 100 scale above the dendrogram indicates the percent identity between fingerprints
compared. The fully automated RiboPrinter has been developed and marketed by Qualicon, a Dupont subsidiary (Warwick, United Kingdom).
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et al. (140) have investigated the seroconversion to M. ca-
tarrhalis in patients who were hospitalized with middle (laryn-
gitis, tracheitis, bronchitis) and lower respiratory tract infec-
tions. They found seroconversion in only 4 (5%) of 76 children
who had M. catarrhalis-positive nasopharyngeal aspirate cul-
tures compared to 4 (1%) of 373 children who had negative
cultures. According to their results, M. catarrhalis is not a likely
cause of these infections in children. However, in contrast to
these findings, several other studies have indeed implicated M.
catarrhalis in lower respiratory tract infections in children.
First, M. catarrhalis has been isolated in pure culture from
secretions obtained by tracheal aspiration in neonates, infants,
and children with pneumonia (15, 21, 107, 155). Underlying
bronchopulmonary dysplasia has been suggested as a predis-
posing factor in these cases (15, 60). Second, in a prospective
study combining microbiological and clinical criteria, M. ca-
tarrhalis was identified as a significant respiratory pathogen in
children (35). Third, both local and systemic antibody re-
sponses to M. catarrhalis infection have been documented in
several studies (25, 51, 90, 91, 101, 102). Pneumonia in children
can be complicated by bacteremia with M. catarrhalis (59, 123,
224). For example, Ioannidis et al. (123) have presented data
on 58 cases of M. cattarhalis bacteremia, including cases in 28
children younger than 12 years. Most patients (ca. 70%) had an
underlying disease (malignancy and/or neutropenia, underly-
ing respiratory tract disorder), and an associated respiratory
tract infection was identified in half of the patients. In children
with bacteremia, skin lesions such as purpuric and petechial
rash were frequent. Of 58 patients, 12 died (21%), including 4
of 5 patients with endocarditis and 4 of 7 patients who did not
receive therapy. In conclusion, although the current literature
does not provide a definite answer, the available data suggest
that M. catarrhalis can be involved in lower respiratory tract
infections in children.
Other Infections
M. catarrhalis has been implicated as a cause of bacterial
tracheitis in childhood (23, 36, 86, 155; V. K. Wong and W. H.
Mason, Letter, Pediatr. Infect. Dis. J. 6:945–946, 1987), for
which preceding viral infection has been considered a signifi-
cant predisposing factor (Wong and Mason, Letter). In addi-
tion, a role for this microorganism has been suggested in con-
junctivitis and keratitis (152, 155), although reports on ocular
infections have been rare (1, 152, 247; R. L. Bergren, W. S.
Tasman, R. T. Wallace, and L. J. Katz, Letter, Arch. Ophthal-
mol. 111:1169–1170, 1993). Finally, one case of fatal meningitis
due to M. catarrhalis has been reported (63).
INFECTIONS IN ADULTS
M. catarrhalis has been associated with a variety of clinical
syndromes in adults; the most frequent are discussed in more
detail below. It has to be emphasized, however, that M. ca-
tarrhalis can also manifest itself as a pathogen in the nosoco-
mial setting. A rare but very serious and frequently lethal
infection with M. catarrhalis appears to be endocarditis (123,
180, 219).
Laryngitis
M. catarrhalis is the most common bacterial species isolated
from adult patients with laryngitis. Schale´n et al. (209, 210)
found that of 40 adults with this disease, 22 were infected by M.
catarrhalis (55%), compared to 0 of 40 healthy adults. Even so,
the exact role of M. catarrhalis, either as an innocent bystander
or as a causal microorganism in the pathogenesis of adult
laryngitis, is not fully understood.
Bronchitis and Pneumonia
M. catarrhalis is not a common cause of lower respiratory
tract infections in healthy adults. However, the bacterium
causes pulmonary infections in three separate clinical settings
(169): (i) in COPD patients, (ii) pneumonia in the elderly, and
(iii) as a nosocomial respiratory tract pathogen.
M. catarrhalis is a common cause of exacerbations in COPD
(35, 43, 64, 83, 108, 160, 165, 178, 182, 192, 208). In COPD and
otitis media, only S. pneumoniae and nontypeable H. influenzae
are isolated more often than M. catarrhalis, yet the frequency
of isolation of M. catarrhalis from sputa has risen during the
past 10 to 15 years (35, 64, 160). This rise cannot be ascribed
only to an increased awareness in the laboratory (64). One
study has shown M. catarrhalis to be the single most isolated
pathogen in COPD (218). Sarubbi et al. (208) reviewed all
respiratory tract cultures (n 16,627) performed over a period
of 42 months and identified M. catarrhalis in 2.7% (n  457) of
these cultures. In this study, M. catarrhalis was found to be the
second most commonly isolated respiratory tract pathogen af-
ter nontypeable H. influenzae but ranking before S. pneu-
moniae. In addition, these and many other authors (62, 64, 69,
192, 208, 251, 252) demonstrated striking seasonality, with
winter and spring being the periods with the greatest incidence
of M. catarrhalis isolation. This pattern is not found with S.
pneumoniae or H. influenzae (64, 69). Preceding viral respira-
tory tract infection caused by respiratory syncytial virus, for
example, could be a factor in the seasonal variations which
have been observed with M. catarrhalis infections, although this
hypothesis remains untested (69, 229).
The typical clinical picture of an M. catarrhalis respiratory
infection is that of tracheobronchitis, presenting with cough
and production of purulent sputum. Pneumonia caused by M.
catarrhalis tends to be a relatively mild disease. It differs from
bronchitis by the presence of mostly lower-lobe infiltrates on
chest X rays (108, 182, 218, 252). High fever, pleuritic pain, and
toxic states are uncommon, as are empyema and bacteremia
(108, 182, 192, 218, 252). Collazos et al. (59) reviewed 15 cases
of bacteremic pneumonia due to M. catarrhalis that had been
reported in the literature. These cases (nine in adults and six in
children) were similar in both characteristics and clinical symp-
toms to those described for patients with bronchitis or pneu-
monia without bacteremia. The mortality rate for these bacte-
remic cases was 13.3%. An even larger review by Ioannidis et
al. in 1995 (123) described the clinical spectrum of M. catarrha-
lis bacteremia in 58 patients. Predisposing factors were present
in more than 70% of the patients and included neutropenia,
malignancy, and respiratory impairment, either alone or in
combination. In this study, maculopapular rash appeared to be
a relatively rare symptom and was most frequently seen in
patients with neutropenia. Mortality was high (29%) among
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patients with underlying respiratory disease, and the infection
was more severe when the patient was coinfected with other
respiratory tract pathogens. The overall mortality related to
respiratory infection appears to be relatively low (around 10%
[12, 108, 252]). Even so, M. catarrhalis pneumonia often occurs
in patients with end-stage pulmonary or malignant disease, and
the short-term mortality in some patient categories is as high as
45% (252). Most patients are elderly (older than 65 years), and
90 to 95% of patients have underlying cardiopulmonary dis-
ease (12, 108, 252), with COPD being present in the majority
of cases. Many patients appear to be malnourished (252). A
large percentage (70%) are smokers or exsmokers (69). Men
appear to be at greater risk than women, although this obser-
vation could be confounded by, for instance, smoking habits
(12, 59, 69, 108, 182).
Research into the colonization and infection of bronchiec-
tasis patients with M. catarrhalis over time has indicated that a
subset of patients (around 20%) appeared to be chronically
colonized with M. catarrhalis, sometimes consecutively with
four different strains. A causal relation between isolation of the
bacterium and exacerbations could not be proven, although its
presence in a large proportion of patients suggests a causal role
(139).
An additional organism can also be isolated from about 40
to 50% of sputum cultures; in most cases, S. pneumoniae or H.
influenzae are isolated (12, 108, 182, 192). For several reasons,
it is important to define the role of M. catarrhalis in these
mixed infections, particularly with respect to the adequate
management of patients and specific antibiotic therapy. In a
mixed infection with S. pneumoniae, for example, should treat-
ment for M. catarrhalis be considered at all, or can antibiotic
treatment be targeted at the pneumococcus alone?
Nosocomial Infections
That nosocomial infections could be caused by M. catarrhalis
has been suggested by several investigators (15, 19, 35, 60, 67,
107, 108, 188, 200). In the past it has been difficult to confirm
the spread of the organism among hospitalized patients, be-
cause of the lack of a reliable typing system. Furthermore,
because of the mildness of the disease, nosocomial spread can
be overlooked or simply disregarded. Patterson et al. (188)
used restriction endonuclease analysis to confirm an outbreak
in a hospital unit. Strains from five patients and two staff
members yielded identical genotype patterns when this tech-
nique was used. During the investigation of another putative
outbreak, immunoblotting with normal human serum was com-
bined with restriction endonuclease analysis to type M. ca-
tarrhalis strains. Six M. catarrhalis isolates from a cluster of
infections involving five patients in a respiratory unit were
shown to be identical to each other and different from other,
unrelated strains from the same institution (200). Both meth-
ods provided good discrimination between strains, but they
were not always in complete agreement (166, 200). Thus, the
use of more than one typing technique was recommended.
Another useful option would be restriction endonuclease anal-
ysis with several enzymes rather than just one. Clear vehicles of
bacterial dissemination have not yet been identified in the
clinical setting. However, Ikram et al. (122) found the nosoco-
mial spread of M. catarrhalis to be common, especially in re-
spiratory wards. They also showed that considerable contami-
nation of the environment with M. catarrhalis may occur,
implying a possible aerosol-mediated mode of dissemination.
Thus, important questions remain to be answered with regard
to the nosocomial spread of M. catarrhalis, including the iden-
tification of the reservoir of infection and the mode(s) of trans-
mission. Person-to-person transmission (122, 161, 188, 200)
and spread from environmental sources (44, 122) have been
implicated in nosocomial transmission on the basis of circum-
stantial evidence; of possible significance is the observation
that the bacterium is able to survive in expectorated sputum for
at least 3 weeks (44). Nursery schools are sites where frequent
exchanges of strains may occur (254). Preliminary data do
reveal that this may indeed be important in the epidemiology
of M. catarrhalis carriage (unpublished observations).
ANTIMICROBIAL SUSCEPTIBILITY
Apart from its almost universal -lactamase-mediated resis-
tance to penicillins and its inherent resistance to trimethoprim,
M. catarrhalis remains universally sensitive to most antibiotics
used in the treatment of respiratory infections (18, 119, 159). A
recent large international study, the Alexander Project 1996–
1997, revealed that 100% of isolates were susceptible to amoxi-
cillin-clavulanic acid, cefixime, chloramphenicol, ciprofloxacin,
and ofloxacin (92). For some antibiotics (cefaclor, ceftriaxone,
and doxycyclin) a small increase (0.5%) in the incidence of
resistant strains was noted over the years. The clinical rele-
vance of this increase is still unknown. Of note, strains that
produce -lactamase are expected to be resistant to penicillin,
ampicillin, amoxicillin, and piperacillin (18, 33, 99, 130).
-Lactamase Production
Before 1970, no M. catarrhalis isolate was observed to pro-
duce -lactamase (48, 245); the first -lactamase-positive
strain was isolated in 1976 (245). By 1980, however, 75% of M.
catarrhalis isolates from the United States produced -lacta-
mase (244). By 1990, about 80% of respiratory M. catarrhalis
isolates from the United States (130) and over 90% of isolates
from England and Scotland were positive for -lactamase (99).
Recent studies from Australia, Europe and the United States
all noted -lactamase production in over 90% of isolates (74,
95, 154, 223, 231, 242, 251). Walker et al. (242) investigated
trends in antibiotic resistance of M. catarrhalis isolates (n 
375) in a single hospital over a 10-year period (1984 to 1994).
During this period, the number of isolates showing -lacta-
mase production increased from 30 to 96%. Moreover, a trend
toward reduced susceptibility to four -lactam antibiotics, pen-
icillin G, ceftriaxone, amoxicillin-clavulanic acid, and imi-
penem, but not cefamandole, was observed (although this was
not clinically relevant). For of penicillin and ceftriaxone, this
trend was due to an increased frequency of -lactamase-posi-
tive isolates. However, the increase in the MIC of amoxicillin-
clavulanic acid and imipenem was not due to the increased
frequency of -lactamase-positive strains but occurred mainly
within the group of -lactamase-positive strains. These obser-
vations indicate either (i) a selection for more efficient -lac-
tamases, (ii) a more efficient production of a -lactamase, or
(iii) selection for additional resistance determinants. Given the
high percentage of strains that produce -lactamase and de-
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spite the fact that successful amoxicillin treatment of patients
infected with -lactamase-positive M. catarrhalis has been re-
ported, clinicians should assume that all isolates of M. catarrha-
lis are resistant to amoxicillin, ampicillin, piperacillin, and pen-
icillin (73, 147).
In M. catarrhalis two types of -lactamases can be found that
are phenotypically identical: the BRO-1 and BRO-2 types.
Both are membrane associated, and they differ by only a single
amino acid. The enzymes are encoded by chromosomal genes,
and these genes can be relatively easily transferred from cell to
cell by conjugation (159, 245). Fortunately, both enzymes are
readily inactivated by -lactamase inhibitors, and all isolates
are still susceptible to amoxicillin in combination with clavu-
lanic acid (119, 159). BRO-1 is associated with higher MICs
than is BRO-2; the difference is attributed to the production of
more enzyme as a consequence of the higher transcriptional
activity of the BRO-1 gene. BRO-1 is the most common en-
zyme and is present in ca. 90% of -lactamase-positive strains
(159, 245). Recent studies have shown that the -lactamase of
M. catarrhalis is lipidated, suggesting a gram-positive origin. M.
catarrhalis is the first gram-negative bacterial species posses-
sing such a lipidated BRO-type -lactamase (31). This adds to
the complexity of the dissemination of antibiotic resistance
traits among M. catarrhalis strains in the sense that there seems
to be a possibility for the acquisition of genes even from the
gram-positive gene pool. The GC content of the BRO genes
provides additional proof of their non-Moraxella origin and
suggests a recent acquisition event. The lack of a genetic bar-
rier between gram-negative and -positive bacterial species is a
reason for clinical concern, and additional research on the
mechanism of DNA uptake by M. catarrhalis is certainly war-
ranted.
-Lactamase from M. catarrhalis not only protects the bac-
teria producing the enzyme but also is thought to inactivate
penicillin therapy of concomitant infections by serious airway
pathogens such as S. pneumoniae and/or nontypeable H. influ-
enzae (37, 38, 42, 115). This phenomenon is referred to as the
indirect pathogenicity of M. catarrhalis. Indeed, in such circum-
stances, treatment failures have been reported (187, 230),
demonstrating the importance of reporting not only pure but
also mixed cultures positive for M. catarrhalis (246).
CELL WALL STRUCTURES
Lipooligosaccharides
Lipooligosaccharide (LOS) is an important virulence factor
of gram-negative bacteria. M. catarrhalis LOS appears to be
semirough, meaning that it contains only one repeating O
antigen at best (96, 118). In addition, it appears to be more
antigenically conserved among strains than does the LOS of
other gram-negative bacteria (171). This suggests that it will
probably not serve as a useful basis for a typing system (71).
Even so, Vaneechoutte et al. were able to distinguish three
LOS types, A, B, and C, by enzyme-linked immunosorbent
assay; these types accounted for more that 95% of all strains.
Type A represents the great majority of strains (61%), with
types B and C containing more limited numbers of strains (29
and 5%, respectively); 5% of strains remain unidentified (228).
The various types can be discriminated by biophysical differ-
ences imposed by the presence of serotype-specific LOS struc-
tures (Fig. 4) (79, 118). There is a common polysaccharide
inner core in serotypes A, B, and C, which can, at least in part,
explain the existing cross-reactivity between the serotypes. The
antigenic specificities of the three serotypes are caused by
differences in terminal sugars of one of the branches (118).
Moreover, a structural overlap was documented with the LPS
moieties from species of the Neisseria and Haemophilus groups.
The LOS of serotype B and C contain oligosaccharide chains
of variable length. This could be due to phase-variable expres-
sion of the biosynthetic genes, as suggested by the presence of
tandem repeats (189). Another explanation offered is that vari-
ations in the activity of enzymes involved in cell wall assembly
(influenced by environmental factors or growth rate, for exam-
ple) result in a different oligosaccharide (118). LOS is also
present in culture supernatants of M. catarrhalis as a part of
subcellular elements called blebs. These small vesicles may
facilitate the distribution of LOS in the host environment.
Whether these structures serve some physiological function is
currently unknown. LOS serotype A, once adequately detoxi-
fied, can be used as a vaccine when conjugated to a protein
carrier (120). Increases in the levels of anti-LOS IgG are ob-
served on immunization. The increased levels of antibodies
enhanced clearance of bacteria from the lungs of mice after an
aerosol-mediated M. catarrhalis infection. Detoxified M. ca-
tarrhalis LOS conjugated to the high-molecular-weight (HMW)
surface protein of nontypeable H. influenzae provides a poten-
tially very interesting bivalent vaccine (see also below).
Peptidoglycan
Regarding the peptidoglycan, the studies by Keller et al.
(135) indicate that M. catarrhalis organisms have a multilay-
ered peptidoglycan architecture. This peptidoglycan layer was
shown to be responsible for the extraordinary capacity of the
organism to trigger various functional capacities of macro-
phages. Secretion of tumor necrosis factor and nitrite metab-
olism plus the cells’ tumoricidal activity were clearly enhanced.
This triggering capacity could be, at least partially, an expla-
nation for the low virulence of M. catarrhalis. It seems as if
peptidoglycan is involved in some sort of suicidal activity, and
further studies into the basic mechanisms of this phenomenon
are certainly needed.
FIG. 4. Schematic structure of the LOS moieties that cover the
surface of the M. catarrhalis cells. Three main serotypes, A, B, and C,
can be discerned, which differ in the nature of the R group. Abbrevi-
ations: D-Galp, D-galactose phosphate; Kdo, 2-keto-3-deoxyoctonate;
GlcpNac, N-acetyllactosamine.
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Outer Membrane Proteins
In contrast to other nonenteric gram-negative bacterial spe-
cies, the outer membrane protein (OMP) profiles of different
M. catarrhalis strains show a high degree of similarity. Using
sucrose gradient purification of M. catarrhalis outer mem-
branes and sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis, Murphy and coworkers identified eight major pro-
teins, designated OMPs A through H, ranging from 21 to 98
kDa (13, 170, 177). OMPs C and D appeared to be two dif-
ferent stable forms of the same protein, the CD protein. The
strong degree of similarity of OMP profiles explains why sero-
typing systems on the basis of OMP profiles are of little epi-
demiological use. On the other hand, these well-conserved
surface proteins could be interesting vaccine candidates. In
recent years the genes for several of these outer membrane
proteins have been mapped and characterized in more detail.
In addition to OMPs A to H, Murphy and Klingman de-
scribed a novel OMP, designated HMW-OMP or ubiquitous
surface protein UspA (138). UspA has recently been shown to
be encoded by two different genes, which share the coding
potential for a homologous, internal protein domain of more
than 90% amino acid sequence homology (4). Additional
UspA-like genes have been discovered (144). Mutation in the
UspA1-encoding gene resulted in an attenuated phenotype:
adherence capacities of the deletion mutant were significantly
decreased (3). Furthermore, it was demonstrated that UspA2
is essential for complement resistance (3, 144). Protein purifi-
cation studies provided proof that the UspA1 protein binds
specifically to HEp-2 cells and has an affinity for fibronectin
(163). The UspA2 protein, on the other hand, preferentially
binds to vitronectin. Both purified proteins are immunogenic
in mice, and immunized animals clear bacteria from their lungs
more rapidly than do nonimmunized mice (163). Genetic stud-
ies have shown that intraspecies variability in the genes can be
attributed mainly to variation in regions of repetitive DNA in
the genes (61). In addition, electron microscopy of M. catar-
rhalis strains has revealed that the UspA1 and UspA2 pro-
teins present as “lollipop-shaped” structures protruding from
the bacterial surface (114). Interestingly, the structure of the
Yersinia adhesin (YadA) protein of Yersinia enterocolitica, a
protein involved in adhesion and defence against complement-
mediated killing, has a very similar overall structural organi-
zation and function (114, 207). Moreover, many related genes
have been identified in the genomes of a wide variety of bac-
terial species, suggesting that the proteins serve essential and
universally required functions. Although the UspA1 and UspA2
antigens currently are the best-studied M. catarrhalis proteins,
their vaccine potential still is matter of ongoing investigations
(see also below).
The heat-modifiable CD OMP could be cloned and ex-
pressed in Escherichia coli. The gene appeared to be strictly
conserved among M. catarrhalis strains (175). Homology was
found with the porin F protein (OprF) of Pseudomonas spp.
(R. de Mot and J. Vanderleyden, Letter, Mol. Microbiol. 13:
379–380, 1994) and with an OmpA-like protein from Acineto-
bacter spp. (184), indicating transspecies conservation that is
generally associated with functional importance. The CD pro-
tein was found to be involved in binding purified human mucin
from the nasopharynx and middle ear but not in binding mucin
from the saliva and tracheobronchial mucin (22). The CD
protein is a potential vaccine candidate (253), and antibodies
raised in mice enhanced clearance in a pulmonary challenge
model (176).
M. catarrhalis expresses both transferrin and lactoferrin re-
ceptors on its surface, named transferrin-binding proteins A
and B (TbpA and TbpB) and lactoferrin-binding proteins A
and B (LbpA and LbpB) (30), respectively. These proteins are
partially homologous at the genetic level. In addition, homol-
ogous proteins of the lactoferrin-binding proteins as well as the
transferrin-binding proteins are found in Neisseria spp., Hae-
mophilus spp., and other gram-negative bacteria. These pro-
teins provide the cell with the capacity to acquire iron by
sequestering it from host carrier proteins (5, 45, 78). The
receptors themselves appear to be significant virulence factors,
since mutation analysis of the transferrin receptor has demon-
strated an impaired growth capacity for the mutated strain.
The receptors are also immunogenic and may be interesting
vaccine candidates (54, 255). Several genes are associated with
this iron acquisition machinery, with some functioning as as-
sociate receptors and others functioning as facilitating factors
(148). Molecular knockout of the gene for transferrin-binding
protein TbpB revealed that in the presence of a TbpB-specific
monoclonal antibody and human complement, the mutant re-
sisted killing, in contrast to the wild type, which was rapidly
killed (149). However, the epitope recognized by the mono-
clonal antibody was surface expressed in only one of three
clinical isolates.
The OMP E antigen appears to be of low immunogenicity,
but it does possess universally surface-expressed epitopes in
different M. catarrhalis strains (24). It is a relatively highly
conserved protein, for which no definite function has yet been
defined, although it may have a function in the uptake of
nutrients (i.e., fatty acids) by the bacterium (173). In addition,
this recent study found an increased sensitivity to complement-
mediated killing in a knockout mutant of OMP E.
Important goals for present and future investigations are to
determine the antigenic variability of OMPs, to find antigens
that generate protective antibodies, and to determine the pre-
cise function of these proteins in the pathogenesis of diseases
caused by the bacterium.
Pericellular Structures
The attachment of bacteria to mucosal epithelial cells is
often mediated by pili or fimbriae. Some studies have provided
evidence for the expression of pili by M. catarrhalis (156),
whereas others have been unable to demonstrate their pres-
ence (7, 110). Consequently, some strains may be pilus positive
whereas others have been proven to lack pili (7, 202). Pili are
composed of polymerized protein subunits called pilins. Marrs
and Weir (156) found several characteristics that point to the
presence of type 4 (MePhe) pili in M. catarrhalis. In addition,
electron microscopic data revealed that besides pili similar to
those of type 4, an additional non-type 4 class of pili exists.
Elucidation of the prevalence and role of these pili in the
pathogenesis and host response to M. catarrhalis requires fur-
ther study (171), although preliminary studies have already
revealed that fimbriated bacteria bind more efficiently to lower
bronchial epithelial cells than nonfimbriated bacteria do (201).
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Capsule
The presence of a polysaccharide capsule has been previ-
ously suggested (7). Capsules are considered to be an impor-
tant virulence factor in both gram-positive and gram-negative
bacteria. Unlike the situation in many other bacterial patho-
gens, the capsule is not detectable when colonies of M. ca-
tarrhalis are examined on agar plates. More research is neces-
sary to definitely demonstrate the presence of a capsule and to
define its role, if any, in virulence.
VIRULENCE
In general, the pathogenicity and virulence of a microorgan-
ism are determined by its ability to avoid host defense mech-
anisms. Smith (215) recognizes five cardinal requirements for a
bacterium to be virulent: (i) binding, colonization, and infec-
tion of mucous surfaces; (ii) entry into host tissues; (iii) mul-
tiplication in the in vivo environment; (iv) interference with
host defense mechanisms; and (v) production of damage to the
host. Relatively little is known about the precise virulence
traits of M. catarrhalis. Below, information will be provided on
bacterial adherence and models of infection, whereas comple-
ment resistance will be presented as an example for some of
these general virulence features. It has to be emphasized, how-
ever, that a complete insight into the full virulence gene rep-
ertoire is still lacking. For example, it has been demonstrated
on the basis of DNA hybridisation studies that M. catarrhalis
harbors homologues of phase-variable H. influenzae virulence
genes (189). The precise nature of these genes has yet to be
elucidated, which implies that on the basis of relatively
straightforward cloning experiments, several new virulence
genes could well be identified in the near future.
Adherence
It is noteworthy that only a small number of studies on the
precise interaction between M. catarrhalis receptors and hu-
man antigens have been undertaken. An elegant study was
presented by Reddy et al. (198). Using a purified middle ear
mucin glycoprotein, they showed that only the CD protein of
M. catarrhalis was capable of establishing a specific interaction
with the sialo version of the human protein. A follow-up study
from the same laboratory revealed immense heterogeneity in
the interaction between upper respiratory tract pathogens and
human mucins (22). In this study, the CD protein of M. ca-
tarrhalis was shown to specifically attach to the mucin mole-
cules from the nasopharynx and middle ear but not to mucin
from the saliva and tracheobronchial mucin. Interactions such
as these represent the first steps in the process of bacterial
colonization and infection. The general mechanism of cellular
adherence of M. catarrhalis to host cell surfaces has been stud-
ied by Rikitomi et al. (202). The presence or absence of fim-
briae did not influence the capacity of the bacterium to adhere
or to cause hemagglutination. Indeed, the mechanisms of bind-
ing appeared different for adherence and hemagglutination.
Another study found no differences between the source of the
isolate (blood or lungs) and hemagglutination (129). Further-
more, these investigators showed that attachment was not de-
termined primarily by lectin-carbohydrate interactions. In con-
trast to the findings of these investigators, an in vitro
adherence study with HEp-2 cell cultures demonstrated that
strains derived from infections adhere more efficiently than do
mere colonizers (94). In addition, data from this latter study on
experimental periodate treatment suggested that bacterial ad-
herence in this artificial system appears to be mediated by
microbial carbohydrate moieties. Of interest, adherence of M.
catarrhalis appeared to be stimulated by neutrophil defensins,
peptides with broad-spectrum antimicrobial activity, released
from activated neutrophils during inflammation, suggesting
that defensin-mediated adherence contributes to persistence
of infection, for instance in COPD patients (104).
A recent study by Ahmed et al. (6) investigated the influence
of charge on adherence. Although bacteria and epithelial cells
are both negatively charged, interaction between the negatively
charged surface of M. catarrhalis cells and positively charged
domains called microplicea on pharyngeal epithelial cells was
found. More research, especially into the role of proteins like
fibronectin, vitronectin, and plasminogen in adhesion, is
needed. The contradictory nature of some of the current ob-
servations only strengthens this suggestion.
Animal Models
The low virulence of M. catarrhalis in laboratory animals has
hampered protection experiments and pathogenicity studies in
rats and mice. Although several studies have been conducted
with different animal species, reports describing a reliable in-
fection model are scarce. A reproducible, but rather artificial,
model was presented by Lee et al. (J. C. Lee, J. C. Hamel, D.
Staperd, and C. W. Ford, Abstr. 93rd Gen. Meet. Am. Soc.
Microbiol., p. 50, abstr. B-137, 1993), who were able to isolate
live M. catarrhalis from a specific mouse strain, C3H/HeN.
Bacteria, suspended in brain heart infusion broth supple-
mented with 8% brewer’s yeast and 0.2% Tween 80, were
inoculated via an intraperitoneal route. Infection resulted in
high mortality and facilitated antibiotic efficacy studies. In an-
other murine model (236), designed to study phagocytic re-
sponses and clearance mechanisms after endotracheal chal-
lenge with M. catarrhalis, a high influx of polymorphonuclear
leukocytes into the lungs was noted. Bacteria were cleared
from the lungs within 24 to 48 h, and the animals remained
healthy. A deficiency in complement component C5 resulted in
a minor delay in clearance. A similar and most frequently used
animal model is a mouse model for the study of pulmonary
clearance of M. catarrhalis (226). This model consisted of
transoral inoculation of bacteria into the lungs under anesthe-
sia and operative exposure of the trachea. Enumeration of
viable bacteria in the lungs involved aseptic removal and ho-
mogenization of the lungs, followed by serial dilution and plat-
ing on agar media. This model permits an evaluation of the
interaction of bacteria with lower respiratory tract epithelium
and the precise assessment of pathologic changes in the lungs.
As an example, using this model, MacIver et al. (151) obtained
evidence that immunization with M. catarrhalis-derived outer
membrane vesicles gives rise to a systemic IgG antibody re-
sponse which is accompanied by enhanced clearance of M.
catarrhalis from the lungs, Kyd et al. (143) used a model of
mucosal immunization involving direct inoculation of killed
bacteria into the Peyer’s patch followed by an intratracheal
booster with dead M. catarrhalis. Enhanced clearance of bac-
VOL. 15, 2002 MORAXELLA CATARRHALIS 135
teria from the lungs was observed, correlating with higher
levels of specific IgA and IgG in serum and bronchoalveolar
lavage fluid. A clear disadvantage of the above models is their
complex and invasive nature, requiring operation techniques
and general anesthesia. In addition, the clearance of M. ca-
tarrhalis from the lungs of mice is relatively rapid (within 6 to
24 h), most probably as a result of the low virulence of M.
catarrhalis for laboratory animals. Moreover, since M. catarrha-
lis inhabits the upper respiratory tract, inhalation models are
preferred over intraperitoneal, endotracheal, or transoral in-
oculation models. An initial report describing a putatively ef-
fective and reproducible inhalation model in mice was recently
published. Moreover, passive and active immunization studies
in this animal model documented improved pulmonary clear-
ance of M. catarrhalis bacteria (120, 121).
Useful infection models in rats have been described only in
the past 2 years. A purulent otitis media could be induced in
Sprague-Dawley rats, for instance (248). This infection pro-
gressed in a relatively mild fashion, lasting for about 1 week.
On immunization, a protection rate of 50% or more was in-
duced. Using the same model, a clear increase in the density of
goblet cells in the middle ear up to 60 days after inoculation of
bacteria was found, suggesting a highly increased mucosal se-
cretory capacity (50). In another rat model, inhalation of heat-
killed M. catarrhalis cells clearly affected the laryngeal mucosa
(125), resulting in a clinical syndrome reminiscent of laryngo-
tracheitis in children. The studies mentioned above suggest
that rats may provide an infection model that is more interest-
ing than was previously thought.
Inoculation of M. catarrhalis into the middle ear of chinchil-
las and gerbils gave rise to effusion, but no live bacteria could
be recovered from the middle ear after 24 h (77). Later studies,
however, revealed the feasibility of studying otitis media in the
chinchilla model. Although chinchillas are not generally avail-
able, PCR would not have reached it current state of applica-
bility without the studies in these animals (10, 11, 193).
In conclusion, despite several drawbacks, mouse models of
pulmonary clearance appear useful in studies of the effects of
vaccination with several M. catarrhalis antigens on clearance of
the bacteria. The rat models appear promising. Suitable animal
models to study the pathogenicity of infection by M. catarrhalis
in any detail are not yet available. This is primarily because
rodents, the best accessible laboratory animals, tend to resist
infection with this microorganism.
Complement Resistance
Complement resistance is considered an important virulence
factor of many gram-negative bacteria, which may explain why
gram-negative bacteria isolated from the blood are largely
complement resistant; these strains are also especially success-
ful in establishing animal models of infection (41, 203). In
general, rough strains of gram-negative bacteria, producing
LPS devoid of O-specific side chains, are highly susceptible to
C5b–9-mediated killing whereas smooth strains, which synthe-
size complete LPS, are often complement resistant (221). Since
the LPS of M. catarrhalis is of the rough type (96), it presum-
ably does not play a major role in complement resistance.
However, Zaleski et al. recently showed that inactivation of
galE, a gene encoding a UDP-glucose-4-epimerase involved in
the biosynthesis of the Gal1-4Gal1-4Glc LOS epitope, re-
sults in enhanced susceptibility to serum-mediated killing
(256). Apparently, deviant LOS structures render strains more
susceptible to complement attack. The structural details facil-
itating these interactions are still unknown. Given that com-
plement resistance is considered an important virulence factor
of neisseriae (68, 127, 153, 199), the similarity between mem-
bers of the neisseriae and M. catarrhalis makes complement
resistance and the underlying mechanism an important subject
for further study.
The clinical relevance of complement resistance was shown
for a group of strains isolated from the sputa of elderly persons
(167). Complement resistance can be considered a virulence
factor of M. catarrhalis: the majority of strains (89%) isolated
from lower respiratory tract infections are resistant to comple-
ment-mediated killing, whereas strains from the upper respi-
ratory tract of children are mostly sensitive (58%) (117; Hol
et al., Letter). Several other authors have tested M. catarrhalis
strains for complement resistance (39, 51, 129, 216; R. E. Winn
and S. L. Morse, Abstr. 84th Annu. Meet. Am. Soc. Microbiol.,
p. 28, 1984). Complement-resistant strains inhibit the terminal
pathway of complement, i.e., formation of the membrane at-
tack complex of complement (233). The binding of human vi-
tronectin, an inhibitor of the terminal pathway of complement,
appears to play a crucial role in complement resistance of M.
catarrhalis (234). In Fig. 5 the binding of human vitronectin to
complement-resistant and complement-sensitive strains of M.
catarrhalis is shown. HMW-OMP, also known as ubiquitous
surface protein A (composed of two separate proteins, UspA1
and UspA2), appears to play a major role (C. M. Verduin, H. J.
Bootsma, C. Hol, A. Fleer, M. Jansze, K. L. Klingman, T. F.
Murphy, and H. Van Dijk, Abstr. 95th Gen. Meet. Am. Soc.
Microbiol., p. 189, abstr. B-137, 1995). Indeed, it was shown
that vitronectin binds to UspA2 (163). Furthermore, a UspA2
mutant strain of M. catarrhalis was sensitive to complement-
mediated killing, whereas the parent strain and an isogenic
mutant with a mutation in UspA1 were resistant (3).
Another study (112) suggested that OMP CopB/OMP B2 is
involved in the resistance of M. catarrhalis to killing by normal
human serum. An isogenic mutant not expressing CopB was
killed by normal human serum, whereas the wild-type parent
strain survived. In addition, the researchers showed that the
CopB- mutant strain was less able to survive in the lungs of
mice (112). Recently, it has been shown that inactivation of the
CopB-encoding gene inhibits iron acquisition from lactoferrin
and transferrin (5), although this may be due to an indirect
effect (29). In addition, CopB had significant homology to
TonB-dependent OMPs, among which is the N. gonorrhoeae
outer membrane protein FrpB. These proteins bind to and
transport several ligands from the environment into the intra-
cellular compartment of the bacterium. These functions are
controlled by the TonB proteins, which are thought to be
involved in energy transduction. Yet another OMP, OMP E,
has also been shown to be involved in complement resistance.
An M. catarrhalis OMP E knockout mutant showed a clear
increase in serum sensitivity (173).
We conclude that complement resistance in M. catarrhalis
probably is a highly multifactorial process, from the perspec-
tives of both the host and the pathogen. Within the near future,
additional bacterial genes involved in the defense against the
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complement system may be discovered, requiring a major re-
search effort to integrate the individual contributions of all the
different molecules into an overall mechanistic scheme.
IMMUNITY
M. catarrhalis-related immunology is a rather confusing area
of the literature. M. catarrhalis infections are restricted to mu-
cosal surfaces and are not systemic. Therefore, the correlation
between systemic antibody responses and protection against
this type of infections is not as straightforward as with systemic
infections caused by other species of gram-negative bacteria. In
addition, technical differences in the assays used in different
studies may account for the lack of consistent results (90, 102).
In general, surface structures of the bacterium are the main
target for an antibody response, and the recognition of major
targets for a protective antibody response is of clear impor-
tance for the development of an efficacious vaccine.
Many aspects of immunity to respiratory tract infections
caused by M. catarrhalis are still unknown; they may include
local factors as mucociliary clearance, aerodynamics, alveolar
macrophage activity, complement-mediated killing, and surfac-
tant activity. These factors play important roles in host defense
against oropharyngeal pathogens (225). The development of
an inflammatory response or specific antibody response may,
however, augment these host defense mechanisms (225). As an
example, in COPD patients, local host defense against respi-
ratory pathogens is relatively poor, and although M. catarrhalis
is not a normal inhabitant of the upper respiratory tract in
adults (69; Ejlerten, Letter), infections caused by M. catarrhalis
are frequent in these patients. This points to an important role
for these local defense mechanisms in nonspecific clearance of
this bacterium.
Bacterial clearance and phagocytic cell responses have been
shown to differ among bacterial species. Streptococci, M. ca-
tarrhalis, and nontypeable H. influenzae appeared to be re-
moved from the lungs of mice through various mechanisms
(186). It was found that, compared to other species, M. ca-
tarrhalis was cleared relatively slowly from the lungs, and a
more pronounced, 400-fold increase in numbers of polymor-
phonuclear leukocytes in the lungs was observed (186). In
addition, it was shown that there was stimulation of adherence
of M. catarrhalis by neutrophil defensins, peptides with broad-
spectrum antimicrobial activitity that are released from acti-
vated neutrophils during inflammation, suggesting that defen-
sin-mediated adherence contributes to persistence of infection,
for instance in COPD patients (104).
Below we will summarize the literature covering the anti-
body responses of humans to whole bacteria and several dif-
ferent antigens of M. catarrhalis.
Antibody Responses to Whole Bacteria
Several authors have investigated antibody responses to M.
catarrhalis in different patient cohorts. Chapman et al. (51)
showed that 18 (90%) of 20 adult patients with lower respira-
tory tract infections due to M. catarrhalis, as defined by strict
clinical criteria, had bactericidal antibodies in their convales-
cent-phase sera whereas only (37%) of 19 had bactericidal
antibody present in their acute-phase sera. Black and Wilson
(25) obtained essentially the same results in a larger-scale
study dealing with IgG antibodies in acute- and convalescent-
phase and control sera from adults with bronchopulmonary
disease. Likewise, an enzyme-linked immunosorbent assay
study showed that 10 of 19 children with AOM to M. catarrhalis
had an increase in serum IgG antibody titers to the bacterium
(146). Comparable results were found in the study of Faden et
al. (90): 8 of 14 young children (younger than 2 years) with
otitis media (57%) showed a rise in the levels of serum anti-
body to their own M. catarrhalis isolate (90). In a recent study
FIG. 5. Electron micrographs of the binding of human vitronectin to complement-resistant (left) and complement-sensitive (right) strains of
M. catarrhalis. Immunogold labeling using antibodies specific for human vitronectin revealed that this protein is effectively bound to the resistant
cells whereas the sensitive strain fails to bind a significant quantity of the human matrix protein. Note that the vitronectin protein seems to be
attached toward the boundaries of the cellular matrix, which may correlate with the protruded orientation of the vitronectin-binding ubiquitous
surface proteins (UspA).
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of infants with otitis media, a specific IgG response (mainly
IgG1 and IgG3) was detected in 10 of 12 children aged 8
months or older compared to 1 of 6 younger children. In
addition, immunoblotting revealed four immunodominant
OMPs, UspA, CopB, TbpB, and a protein of 60 kDa, probably
OMP CD (158).
Antibodies to M. catarrhalis are very low or absent in chil-
dren younger than 1 year, and the development of an antibody
response in children, especially of the IgG3 subclass, correlates
with a decrease in colonization. In addition, antibodies to
OMPs of M. catarrhalis, mainly of the IgG3 subclass, appear
around the age of 4 years (56, 102). Furthermore, failure to
produce significant levels of IgG3 antibodies against M. ca-
tarrhalis predisposes to infection with the bacterium (100). In
addition, all adults appeared to have antibodies to M. catarrha-
lis (56, 102). Data gathered during studies focusing on single-
protein responses indicate that normal children and adults
develop a systemic, M. catarrhalis-specific IgG response that
may be protective. Again, this may in part explain the differ-
ences between children and adults when the colonization rate
is considered (9, 52, 56, 89, 102; Ejlersten, Letter).
Lipooligosaccharide Immunogenicity
With regard to LOS, it was reported that antibody responses
to these surface structures constitute a major part of the hu-
moral immune response during infection with M. catarrhalis.
This antibody response is not serotype specific but is directed
to common epitopes of the LOS of different M. catarrhalis
serotypes (185, 197). Hence, M. catarrhalis LOS may be of
interest for evaluation as a possible vaccine candidate. The
usefulness of the LOS surface structures for the development
of a vaccine requires more knowledge about the role of these
structures in the pathogenesis of disease and the accompanying
immune response, although preliminary results are already
promising (105, 120).
Immunogenicity of Outer Membrane Proteins
Much research nowadays is focused on the identification and
characterization of OMPs of M. catarrhalis as suitable vaccine
candidates. OMP B1, CopB/OMP B2, LbpB, OMP CD, OMP
E, OMP G, TbpB, and UspA have all been mentioned as
potential vaccine candidates (53, 111, 158, 168, 172, 173, 175,
212, 253, 255). In contrast, no antibody response to TbpA or
LbpA could be detected in convalescent-phase sera from pa-
tients with pulmonary infections, limiting their role as vaccine
candidates (255). Hansen and coworkers showed that CopB/
OMP B2 is a target for antibodies that increase pulmonary
clearance in the mouse (111). Another study has demonstrated
that CopB is essentially well conserved and that most strains
react with CopB-specific monoclonal antibodies (212). How-
ever, certain regions in the protein show interstrain variability;
therefore, if this protein is to be developed into a candidate
vaccine, only its conserved regions should be targeted. Sethi et
al. (211) found a predominant antibody response to a minor
84-kDa OMP, designated OMP B1, OMP CD does not appear
to be an immunodominant antigen, as indicated by the fact that
there is an absence of a new antibody response to this protein
after exacerbation of M. catarrhalis infection in COPD pa-
tients. Furthermore, the high degree of sequence conservation
suggests that there is no immune selective pressure. Still, the
purified antigen could be a promising vaccine candidate (174,
253). Helminen et al. (111) also presented evidence that UspA
may be a target for protective antibodies in humans. Chen et
al. (53) immunized mice with purified UspA and subsequently
challenged these mice intratracheally with M. catarrhalis. Six
hours after challenge, approximately 50% fewer bacteria were
isolated from the lungs of the immunized mice than from the
lungs of the nonimmunized control mice. In addition, antibod-
ies induced complement-dependent bacterial killing of heter-
ologous M. catarrhalis strains (53). The finding that IgG3 is a
major contributing factor in the immune response to M. ca-
tarrhalis was confirmed by a study by Chen et al. of the immune
response of healthy adults and children to UspA1 and UspA2
(52). In a small cohort of children suffering from otitis media,
antibodies specific for UspA1 and UspA2 could be identified
(206). The amounts of these specific antibodies varied strongly
with age (205). IgG antibody titers to UspA were low during
the first 2 years of life and reached a maximum only during
adulthood, whereas no specific IgA to UspA could be detected
in nasopharyngeal secretions of young children. Considering
the age-dependent differences in antibody prevalence, the
question on whether to vaccinate against M. catarrhalis remains
relevant.
Local Antibody Response
Only a few investigators have studied the development of
antibody responses in the middle ear fluid of children with
otitis media (89, 90, 133, 220). IgG and IgA appeared to be
produced locally in the majority of patients, but antibodies
derived from serum were also detected in middle ear fluids of
patients with otitis media. Faden et al. (90) showed that middle
ear fluid IgG, IgM, or IgA antibody was produced in 100, 29,
and 71% of the children, respectively. Of interest, many chil-
dren with local antibodies in their middle ear fluid did not
develop a systemic antibody response. Local antibodies may
play an important role in the recovery from and prevention of
AOM (102).
In a study focusing on local IgA antibodies to UspA in the
nasopharyngeal secretions of children colonized by M. ca-
tarrhalis, no response was detected (205).
Since M. catarrhalis is a primarily mucosal pathogen, more
detailed studies of local immune responses are urgently
needed, and the role of IgA antibodies in resistance to M.
catarrhalis infection clearly needs more attention.
Vaccines
The development of vaccines for the prevention of M. ca-
tarrhalis-mediated disease is currently a hot topic. The most
promising vaccine candidates have recently been reviewed by
McMichael (162). Most of the molecules that have raised peo-
ple’s hopes have been described in the previous section of this
review and need not be reiterated here. However, the combi-
nation of data that is available in today’s literature suggests
that the development of an M. catarrhalis vaccine is well under
way: animal models of infection have been developed and
described, and several vaccine candidate molecules have been
studied with respect to prevalence and genetic conservation
among different isolates. Although new candidate molecules
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are regularly brought forward (93), relatively little or nothing is
known about the optimal routes for vaccine delivery or
whether there is a need for adjuvants. A recent study, using a
rat model, suggests that the mucosal route of delivery for M.
catarrhalis is more effective than systemic immunization (142).
However, no decisive data are available. It will probably still
take more than a decade before the first vaccines for genuine
clinical use will become available.
CONCLUDING REMARKS
It has become evident over the past decades that M. ca-
tarrhalis has significant pathogenic potential. Classical antibi-
otic treatment alleviates the clinical burden, but in the end,
only effective vaccination may prevent the development of
disease. For example, AOM is a major cause of morbidity in
early childhood and is responsible for an estimated 25 million
physician visits and $3.8 billion of medical expenditures annu-
ally. Since M. catarrhalis is one of the three major pathogens in
AOM, vaccination could constitute a significant and cost-ef-
fective health benefit. Many potential vaccination strategies
have been suggested over the years, but clinical trials have not
yet been conducted. Effective immunity seems to be acquired
during the first 10 years of life. The group of children that
suffers from recurrent otitis media caused by M. catarrhalis may
be problematic; for these patients, vaccination may in the end
provide an important relief. For the future, identification of
important physiological response regulators may be helpful in
the identification of novel therapeutic targets (164). In addi-
tion, M. catarrhalis genomics should be strengthened: knowl-
edge of the whole genome sequence, preferably for both com-
plement-resistant and complement-susceptible isolates, should
be instrumental in the recognition of immunologically relevant
genes and regulators. At the time of writing this review, only a
gross genetic map is available (181). The genome sequence
itself is still eagerly awaited.
In conclusion, over the past two decades M. catarrhalis has
evolved from an emerging to a well-established pathogen. In-
deed, -lactamase-producing isolates appear to be widespread,
and this may play an important role in the therapy of infec-
tions, particularly in the treatment of mixed infections. If
novel, specific, and effective modes of disease treatment or
prevention (including vaccination) are to be developed for M.
catarrhalis infections, then further research into the fundamen-
tal nature of M. catarrhalis pathogenicity will be required.
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